Histone methyltransferase inhibitors

The present disclosure provides certain compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies such as beta-thalassemia and sickle cell disease. Als...

Full description

Saved in:
Bibliographic Details
Main Authors Setti, Lina Q, Li, Zhe, Yu, Ming
Format Patent
LanguageEnglish
Published 22.02.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present disclosure provides certain compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies such as beta-thalassemia and sickle cell disease. Also provided are pharmaceutical compositions containing such compounds as well as processes and intermediates for preparing such compounds.
Bibliography:Application Number: US201716076307